Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Molecular Diagnostic Test for Lung Cancer Is Highly Accurate

By Biotechdaily staff writers
Posted on 09 Oct 2007
A study found that a molecular diagnostic test for lung cancer demonstrated high levels of accuracy.

A standardized reverse transcription polymerase chain reaction (StaRT-PCR) platform technology was used for measuring messenger RNA (mRNA) transcripts levels of 15 genes that could serve to predict lung cancer. More...
The test for these genes, in normal cells sampled via bronchoscopy, identified those individuals genetically at risk for lung cancer. In a study of 49 subjects, the test was able to correctly identify the individuals with cancer 96% of the time.

James C. Willey, M.D., founder and chief science and medical consultant to the company Gene Express (Toledo, OH, USA), and colleagues from the University of Toledo (OH, USA) measured transcript abundance (TA) of 15 genes that encode protective antioxidant and DNA repair proteins in lung airway cells taken from 25 people with lung cancer and 24 people without the disease. Their previous research allowed them to determine the threshold levels of TA for each gene--the point at which the amount of mRNA transcripts would indicate a tendency toward cancer. In this study, they used the threshold levels as a basis to assign a value of one or zero to each of the targeted genes for an individual subject, with "zero” indicating normal TA.

If the sum total of a subject's target genes was greater than or equal to seven, the genes could collectively serve as a biomarker for lung cancer. The results yielded one false negative and seven false positives among the 49 individuals assessed. According to Dr. Willey, a positive result in a subject without lung cancer may not actually be a false positive, but rather could mean that the person is at an increased risk for lung cancer, which might arise later.

"Overall, the study showed a high degree of accuracy for picking out lung cancer patients,” said Dr. Willey. CEO of Gene Express, Gerald Vardzel added, "We are excited about these results, as they demonstrate the value of our platform technology in the development of molecular diagnostics and the movement towards personalized medicine.”

The study was presented at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development in September 2007, which was held in Atlanta, GA (USA).


Related Links:
Gene Express
University of Toledo

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.